Research graph
References from Healthcare resource utilization and associated costs among patients with migraine in Finland: A retrospective register-based study. Local targets link to admitted publications; unresolved targets remain external evidence.
Migraine
10.1038/s41572-021-00328-4 · 2022 · External reference
Migraine
10.1016/s0140-6736(18)30478-1 · 2018 · External reference
Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
10.1016/s1474-4422(18)30322-3 · 2018 · External reference
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates
10.1186/s10194-022-01402-2 · 2022 · External reference
My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland
10.1186/s10194-020-01185-4 · 2020 · External reference
Unresolved reference
External reference
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
10.1111/head.12601 · 2015 · External reference
Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans
10.1111/head.12164 · 2013 · External reference
Switching patients with migraine from sumatriptan to other triptans increases primary care costs
10.1111/j.1368-5031.2004.00292.x · 2004 · External reference
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
10.1186/s10194-022-01502-z · 2022 · External reference
CGRP as the target of new migraine therapies—successful translation from bench to clinic
10.1038/s41582-018-0003-1 · 2018 · External reference
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
10.1177/0333102416678382 · 2017 · External reference
Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
10.1007/s40122-021-00331-3 · 2021 · External reference
My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed
10.1186/s10194-018-0946-z · 2018 · External reference
Unresolved reference
External reference
Burden of migraine in Finland: Health care resource use, sick-leaves and comorbidities in occupational health care
10.1186/s10194-019-0964-5 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study
10.1111/head.14259 · 2022 · External reference
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study
10.1007/s10198-022-01507-0 · 2023 · External reference
Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland—a matched cohort study
10.1186/s12888-022-04115-7 · 2022 · External reference
Unresolved reference
2017 · External reference
Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece
10.1007/s40261-019-00827-z · 2019 · External reference
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
10.1186/s10194-022-01492-y · 2022 · External reference
Koko Suomen perusterveydenhuollon asiakaskirjo on nyt kuvattu
2019 · External reference
Poor medical care for people with migraine in Europe—evidence from the Eurolight study
10.1186/s10194-018-0839-1 · 2018 · External reference
The economic cost of brain disorders in Europe
10.1111/j.1468-1331.2011.03590.x · 2012 · External reference
Burden and costs of migraine in a Swedish defined patient population—A questionnaire-based study
10.1186/s10194-019-1015-y · 2019 · External reference
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
10.1186/s10194-020-01162-x · 2020 · External reference
Sickness absence among female employees with migraine and co-existing conditions
10.1111/j.1468-2982.2008.01649.x · 2008 · External reference
